DANIEL M. MILLER Partner (604) 630-5199 FAX (604) 687-8504 miller.dan@dorsey.com |
July 6, 2020
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
USA
Attention: Division of Corporation Finance, Office of Life Sciences
Re: | InMed Pharmaceuticals Inc. |
Amendment No. 1 to Registration Statement on Form S-1
Submitted June 19, 2020
CIK No. 0001728328
Dear Sirs and Mesdames:
On behalf of our client, InMed Pharmaceuticals Inc. (the Company), and pursuant to the Securities Act of 1933, as amended (the Act), and the rules and regulations thereunder, we transmit for your review the Companys responses, as we have been informed by the Company, to the Staffs letter of comment, dated June 26, 2020 (the Comment Letter), in respect of the above noted registration statement. The Companys response below is keyed to the heading and comment number contained in the Comment Letter.
Registration Statement on Form S-1 filed on June 19, 2020
Business
Our Product Candidates and Technologies
Key Milestones, page 79
1. | We note your response to comment 3. It appears that your Collaborative Research Agreement with the University of British Columbia is material to your business. Please disclose in the Summary section that such agreement may be terminated by either party upon 30 days written notice, as referenced on page 78. |
The requested revisions have been made in the noted section, as well as to a related risk factor in the section entitled Risk Factors, of Amendment No. 1 to the Registration Statement on Form S-1.
DORSEY & WHITNEY LLP · WWW.DORSEY.COM · T 604.687.5151 · F 604.687.8504
SUITE 1605 · 777 DUNSMUIR STREET · P.O. BOX 10444 · PACIFIC CENTRE · VANCOUVER, BRITISH COLUMBIA CANADA V7Y 1K4
USA CANADA EUROPE ASIA
U.S. Securities and Exchange Commission
July 6, 2020
Page 2
The Company has also made additional revisions in Amendment No. 1 to the Registration Statement on Form S-1, in order to reflect the Companys recently completed share consolidation and certain other matters.
* * *
Should you have further comments or require further information, or if any questions should arise in connection with this submission, please call the undersigned at (604) 630-5199. You also may email me at miller.dan@dorsey.com or fax me at (604) 687-8504.
Yours truly,
/s/ Daniel M. Miller
Daniel M. Miller
cc: | Eric A. Adams |
Bruce S. Colwill
InMed Pharmaceuticals Inc.
DORSEY & WHITNEY LLP
@"]864>GV:6T
M19@O+.YRSL>K$]R30!FM<&P\0WLLMM